Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Captrust Financial Advisors

Captrust Financial Advisors raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 33.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,091 shares of the medical equipment provider’s stock after buying an additional 9,005 shares during the quarter. Captrust Financial Advisors’ holdings in Lantheus were worth $3,961,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. CreativeOne Wealth LLC raised its stake in Lantheus by 10.7% during the third quarter. CreativeOne Wealth LLC now owns 5,167 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 499 shares in the last quarter. Glenmede Trust Co. NA acquired a new stake in Lantheus during the third quarter valued at approximately $540,000. Prosperity Financial Group Inc. raised its stake in Lantheus by 12.6% during the third quarter. Prosperity Financial Group Inc. now owns 4,137 shares of the medical equipment provider’s stock valued at $454,000 after buying an additional 464 shares in the last quarter. Pekin Hardy Strauss Inc. acquired a new stake in shares of Lantheus during the 3rd quarter worth approximately $225,000. Finally, Centaurus Financial Inc. raised its position in shares of Lantheus by 13.0% during the 3rd quarter. Centaurus Financial Inc. now owns 3,103 shares of the medical equipment provider’s stock worth $341,000 after purchasing an additional 357 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH stock opened at $88.51 on Wednesday. The business has a 50 day simple moving average of $100.44 and a 200 day simple moving average of $97.49. The firm has a market capitalization of $6.15 billion, a price-to-earnings ratio of 14.73 and a beta of 0.45. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Analysts Set New Price Targets

LNTH has been the topic of a number of research reports. JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.71.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.